Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.

[1]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[2]  O. Yokosuka,et al.  Efficacy and safety of entecavir in nucleoside‐naive, chronic hepatitis B patients: Phase II clinical study in Japan , 2009, Journal of gastroenterology and hepatology.

[3]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  P. Marcellin,et al.  Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B , 2008, Hepatology.

[5]  Y. Liaw,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update , 2008, Hepatology international.

[6]  R. Gish,et al.  Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901 , 2007 .

[7]  J. Jang,et al.  A 13‐year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis , 2007, Journal of viral hepatitis.

[8]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[9]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[10]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[11]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[12]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[13]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[14]  N. Hayashi,et al.  P.109 Efficacy and safety of entecavir and lamivudine in japanese adult patients with chronic hepatitis B infection: a phase 2 clinical trial , 2006 .

[15]  A. Bisceglie,et al.  Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .

[16]  M. Campbell.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BLau GKK, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (Univ of Hong Kong, China; et al) N Engl J Med 352:2682–2695, 2005§ , 2006 .

[17]  M. Yuen,et al.  Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications , 2005, Gut.

[18]  I. Ng,et al.  Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core‐promoter and precore mutations , 2005, Journal of viral hepatitis.

[19]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[20]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[21]  J. Hou,et al.  Epidemiology and Prevention of Hepatitis B Virus Infection , 2005, International journal of medical sciences.

[22]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[23]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[24]  S. Kashiwagi,et al.  Double point mutation in the core promoter region of hepatitis B virus (HBV) genotype C may be related to liver deterioration in patients with chronic HBV infection , 2004, Journal of Gastroenterology and Hepatology.

[25]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[26]  M. Mizokami,et al.  Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: A prospective study , 2003, Journal of medical virology.

[27]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[28]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[30]  S. Kashiwagi,et al.  Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. , 2002, The American journal of tropical medicine and hygiene.

[31]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[32]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[33]  N. Leung,et al.  Chronic hepatitis B virus infection in Asian countries , 2000, Journal of gastroenterology and hepatology.

[34]  Chien-Jen Chen,et al.  Epidemiology of hepatitis B virus infection in the Asia–Pacific region , 2000, Journal of gastroenterology and hepatology.

[35]  H. Okamoto,et al.  Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. , 1999, Journal of virological methods.

[36]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[37]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[38]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[39]  F. Kinjo,et al.  Natural seroconversion from hepatitis be antigen to antibody among hepatitis B virus carriers in Okinawa islands , 1991, Journal of medical virology.

[40]  H. Thomas,et al.  Treatment of chronic hepatitis B infection. , 1990, Pharmacology & therapeutics.